During the last session, Sangamo Therapeutics Inc (NASDAQ:SGMO)’s traded shares were 44.35 million, with the beta value of the company hitting 1.17. At the end of the trading day, the stock’s price was $1.02, reflecting an intraday loss of -56.41% or -$1.32. The 52-week high for the SGMO share is $3.18, that puts it down -211.76 from that peak though still a striking 70.59% gain since the share price plummeted to a 52-week low of $0.30. The company’s market capitalization is $92.77M, and the average intraday trading volume over the past 10 days was 13.36 million shares, and the average trade volume was 8.78 million shares over the past three months.
Sangamo Therapeutics Inc (SGMO) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.88. SGMO has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Sangamo Therapeutics Inc (SGMO) registered a -56.41% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -56.41% in intraday trading to $1.02, hitting a weekly high. The stock’s 5-day price performance is -57.32%, and it has moved by -54.87% in 30 days. Based on these gigs, the overall price performance for the year is 87.74%. The short interest in Sangamo Therapeutics Inc (NASDAQ:SGMO) is 19.61 million shares and it means that shorts have 3.54 day(s) to cover.
The consensus price target of analysts on Wall Street is $12, which implies an increase of 91.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $19 respectively. As a result, SGMO is trading at a discount of -1762.75% off the target high and -390.2% off the low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Statistics show that Sangamo Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Sangamo Therapeutics Inc (SGMO) shares have gone up 218.65% during the last six months, with a year-to-date growth rate more than the industry average at 20.34% against 16.70. In the rating firms’ projections, revenue will decrease -65.51% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.32M as predicted by 6 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 31.5M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 2.04M and 481k respectively. In this case, analysts expect current quarter sales to grow by 405.22% and then jump by 6,448.86% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -15.96%. While earnings are projected to return 68.33% in 2025.
SGMO Dividends
Sangamo Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
Sangamo Therapeutics Inc insiders own 2.36% of total outstanding shares while institutional holders control 26.97%, with the float percentage being 27.62%. WASATCH ADVISORS LP is the largest shareholder of the company, while 127.0 institutions own stock in it. As of 2024-06-30, the company held over 20.09 million shares (or 11.1403% of all shares), a total value of $7.2 million in shares.
The next largest institutional holding, with 14.06 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 7.7963% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.04 million.
Also, the Mutual Funds coming in first place with the largest holdings of Sangamo Therapeutics Inc (SGMO) shares are Wasatch Ultra Growth Fund and Wasatch Microcap Fund . Data provided on Sep 30, 2024 indicates that Wasatch Ultra Growth Fund owns about 10.97 shares. This amounts to just over 5.26 percent of the company’s overall shares, with a $11.19 million market value. The same data shows that the other fund manager holds slightly less at 5.65, or about 2.71% of the stock, which is worth about $5.76 million.
